The Prescription Trap: Why Britain's Corporate Doctors Keep Prescribing Yesterday's Medicine for Tomorrow's Problems
In the executive suites of Britain's major holding companies, a familiar ritual plays out whenever subsidiary performance disappoints. Boards convene emergency sessions, consultants are summoned, and within weeks, a predictable sequence of interventions unfolds: costs are slashed, leadership is reshuffled, and marketing budgets are redirected toward rebranding exercises. Yet despite this flurry of activity, fundamental problems persist, and performance rarely improves sustainably.
This pattern reveals a troubling truth about British corporate governance: when faced with underperformance, even sophisticated leadership teams default to interventions that feel decisive while avoiding the more complex work of genuine diagnosis.
The Comfort of Familiar Failures
The standard turnaround playbook has become so entrenched that it operates almost automatically. Cost reduction provides immediate impact on profit margins, creating the appearance of swift action. Leadership changes signal accountability and fresh thinking to stakeholders. Rebranding suggests strategic renewal and market repositioning.
Each intervention carries psychological appeal for boards under pressure. Cost cutting delivers measurable results within quarterly reporting cycles. New leadership appointments generate positive press coverage and demonstrate board responsiveness. Brand refreshes create visible evidence of change that can be communicated to investors and customers alike.
However, this toolkit consistently addresses symptoms rather than causes. Poor performance in subsidiary businesses rarely stems from excessive costs, inadequate leadership, or outdated branding in isolation. More often, it reflects fundamental misalignment between strategy and market reality, operational inefficiencies that transcend personnel, or structural problems that cosmetic changes cannot resolve.
The Psychology of Strategic Repetition
Why do intelligent, experienced executives persist with approaches that have demonstrably failed? The answer lies in the intersection of cognitive bias and institutional pressure.
Confirmation bias leads decision-makers to interpret mixed results as validation of their approach. When cost reduction generates short-term profit improvements, boards focus on these gains rather than underlying revenue decline. When new leadership initially energises teams, temporary enthusiasm is mistaken for sustainable transformation.
Meanwhile, institutional pressure demands visible action within compressed timeframes. Boards cannot tell shareholders they are conducting six-month diagnostic studies while performance deteriorates. The perceived need for immediate response pushes leadership toward interventions that can be implemented quickly, regardless of their ultimate effectiveness.
The availability heuristic compounds these pressures. Executives naturally gravitate toward solutions they have seen before, particularly those that have generated positive feedback from stakeholders. The fact that such interventions may have failed to deliver lasting results becomes secondary to their perceived acceptability.
The Performance of Progress
This dynamic creates what might be termed "performative transformation"—the appearance of strategic action without substantive change. Organisations become skilled at executing turnaround theatre: conducting restructuring programmes, announcing strategic reviews, and implementing change management initiatives that generate activity without addressing fundamental issues.
The performance becomes self-reinforcing. Stakeholders, including board members, investors, and subsidiary management teams, become complicit in maintaining the fiction that familiar interventions represent genuine progress. Everyone understands their role in the script, and everyone benefits from the temporary relief that decisive action provides.
British corporate culture, with its emphasis on pragmatism and measured response, proves particularly susceptible to this trap. The preference for incremental adjustment over radical reimagining means that fundamental problems are addressed through accumulated marginal changes rather than comprehensive reconstruction.
The Diagnostic Alternative
Genuine turnaround success requires abandoning the comfort of familiar interventions in favour of rigorous diagnosis. This means investing time and resources in understanding why performance declined before determining how to restore it.
Effective diagnosis begins with challenging assumptions about the business model itself. Is the subsidiary's value proposition still relevant to its target market? Do its operational capabilities align with customer requirements? Are its competitive advantages sustainable given industry evolution?
The process must examine structural factors that transcend individual performance. How do reporting relationships affect decision-making speed? Where do corporate policies create operational constraints? What cultural dynamics inhibit adaptation and innovation?
Most importantly, diagnostic rigour requires acknowledging that some underperformance reflects strategic miscalculation rather than execution failure. Sometimes the original investment thesis was flawed, market assumptions proved incorrect, or competitive dynamics shifted beyond prediction.
Rebuilding Intervention Capability
Moving beyond the prescription trap requires developing new organisational capabilities for strategic intervention. This means building diagnostic expertise within holding company teams, establishing decision-making frameworks that prioritise understanding over action, and creating governance structures that support longer-term transformation efforts.
Successful corporate groups are beginning to distinguish between crisis management and strategic recovery. They maintain separate protocols for addressing immediate financial distress versus underlying business model problems. They invest in developing internal capabilities for business analysis that complement rather than substitute for external consulting expertise.
Most critically, they have learned to resist stakeholder pressure for immediate visible action when fundamental problems require extended investigation and gradual reconstruction.
The Path Forward
For Britain's holding companies, breaking free from the prescription trap represents both opportunity and necessity. Markets are evolving too rapidly for organisations to succeed through repeated application of outdated intervention methods. Competitive advantage increasingly flows to corporate groups that can diagnose accurately and respond appropriately rather than simply act decisively.
This transformation requires courage—the courage to admit when traditional approaches have failed, the courage to invest time in understanding rather than acting, and the courage to pursue unfamiliar solutions when familiar ones prove inadequate. For British corporate leadership, this may represent the most important strategic capability of the coming decade.
